Vivani

Vivani Medical: “The only company actively developing a GLP-1 implant.”    CEO Adam Mendelsohn discusses this and more on the most recent episode of The Healthcare Technology Report podcast.    #VivaniMedical #NanoPortal #ChronicDisease #DrugDelivery #HealthcareInnovation #GLP1

Last month Vivani CEO Adam Mendelsohn joined Drug Delivery Leader’s “Sit and Deliver” podcast to discuss how ultra long-acting implants could transform care for patients with obesity and Type 2 diabetes.     By improving adherence and convenience, Vivani’s technology-forward approach aims to unlock the full potential of GLP-1 therapies.    Listen to the full conversation here: https://lnkd.in/euqx-yqV.     #DrugDelivery #GLP1 #VivaniMedical #ChronicCare #HealthcareInnovation #SitAndDeliver 

A message from Vivani CEO and Co-Founder Adam Mendelsohn, PhD., regarding yesterday’s announcement of Eli Lilly and Novo Nordisk’s agreement with the Trump Administration to reduce the prices of GLP-1 drugs for patients in the United States. “Yesterday’s announcement validates what we have long known: GLP-1 therapies are essential to improving the health of Americans struggling with obesity, diabetes, and other serious conditions for which GLP-1 medications are indicated to treat now and may be indicated to treat in the future. At Vivani, we applaud the private sector and Federal Government on this historic deal that has the potential to benefit millions of people by making these life-changing solutions more accessible in treating a variety of conditions. As the only developer of miniature, subdermal GLP-1 drug implants designed for once or twice-yearly dosing, we aim to provide the next generation of GLP-1 treatment options and continue to provide expanded access to these incredible medicines.”   #VivaniMedical #GLP1 #ObesityTreatment #DrugDeliveryInnovation #MedTech #HealthcareInnovation #PatientImpact

Our CEO and co-founder Adam Mendelsohn, PhD, joined BioBiz Buzz to discuss the next generation of GLP-1 delivery with miniature drug implants.   While GLP-1s are transformative for diabetes and obesity, there continues to be challenges with poor adherence and tolerability. Miniature subdermal implants with once or twice-yearly dosing have the potential to revolutionize the future treatment of chronic disease.   Listen to Adam’s conversation: https://lnkd.in/eY8ReH7A   #GLP1 #obesity #diabetes #chronicdisease #DiabetesAwarenessMonth

Last month, Vivani Medical announced plans to initiate a Phase 1 clinical study for NPM-139, our investigational semaglutide implant for chronic weight management.    With the potential for Wegovy®-level efficacy and once or twice-yearly dosing, NPM-139 could redefine treatment for obesity and related conditions.    Read the full update: https://lnkd.in/eeKrq9Er.     #VivaniMedical #GLP1 #ObesityTreatment #DrugDeliveryInnovation #ClinicalDevelopment #MedTech 

On National Make a Difference Day, we celebrate the mission that drives us every day at Vivani Medical — improving lives through innovative, long-term healthcare solutions.    From our team to our technology, everything we do is focused on making a meaningful impact for patients everywhere.    #MakeADifferenceDay #VivaniMedical #HealthcareInnovation #PatientImpact 

With more than 1.7 billion people living with obesity globally, The Lancet Group reports that the likelihood of reaching age 70 drops from 80% to 50% for obese adults with a 40-50 BMI.    At Vivani Medical, we’re working to change that trajectory through innovative, long-acting drug delivery solutions designed to support chronic weight management.    #VivaniMedical #ObesityAwareness #DrugDeliveryInnovation #GLP1 #PublicHealth #MedTech 

Vivani Medical believes that our lead implantable semaglutide asset, NPM-139, may offer improved tolerability over current oral and injectable GLP-1 therapies by maintaining steady drug levels and eliminating missed doses — key factors in reducing GI side effects.    Adam Mendelsohn     #VivaniMedical #GLP1 #DrugDeliveryInnovation #PatientCenteredCare #ChronicDisease 

At Vivani Medical, we’re addressing a critical unmet need: the limitations of traditional drug delivery. Millions of patients struggle with adherence, side effects, and inconsistent therapeutic outcomes — especially in chronic conditions where long-term treatment is essential.    Our implantable drug delivery systems are designed to change that. By combining biotechnology and engineering, we aim to deliver precise, long-acting therapies that improve outcomes and reduce burden — for patients, providers, and the healthcare system.    We believe the way medicine is delivered should be as advanced as the medicine itself.    #VivaniMedical #DrugDeliveryInnovation #MedTech #PatientCenteredCare #HealthcareTransformation #Biotech

Last month, Vivani Medical announced rapid progress on NPM-139, our long-acting semaglutide implant for chronic weight management.    With strong Phase 1 and preclinical data, we’re prioritizing NPM-139 for clinical development in 2026.    Read more: https://lnkd.in/eETJ2XeG.    #VivaniMedical #NPM139 #ObesityCare #GLP1 #DrugDelivery #HealthcareInnovation